BIO-TECHNE Fuels Growth with Strategic Acquisitions, Strong Core Segments

TL;DR

**TECH is a buy, as its aggressive M&A strategy and strong core segments are set to capitalize on high-growth biotech markets.**

AI Summary

BIO-TECHNE Corp (TECH) reported a robust fiscal year ended June 30, 2025, with its Protein Sciences segment contributing approximately 72% of net sales and the Diagnostics and Spatial Biology segment contributing 28%. The company continues to execute a disciplined strategy focused on organic growth and strategic acquisitions, exemplified by the investment in Spear Bio in fiscal 2025 and the acquisition of Lunaphore SA in fiscal 2024. A significant 19.9% investment in Wilson Wolf Corporation was made in fiscal 2023, with plans for full acquisition by calendar year 2027. Key product brands like R&D Systems, Tocris Biosciences, Novus Biologicals, and ProteinSimple drive the Protein Sciences segment, while Advanced Cell Diagnostics (ACD), Exosome Diagnostics, and Asuragen lead the Diagnostics and Spatial Biology segment. The company faces risks related to supply chain disruptions and intense competition in the life science research, diagnostics, and bioprocessing markets. Strategic outlook includes expanding global sales staff and distribution channels to enhance customer experience and fostering an 'EPIC' culture for talent development.

Why It Matters

BIO-TECHNE's strategic focus on both organic growth and targeted acquisitions, like Lunaphore SA and Wilson Wolf, positions it strongly in the competitive life science and diagnostics markets. This approach provides investors with exposure to high-growth areas such as cell and gene therapy and spatial biology, potentially driving long-term shareholder value. For employees, the company's 'EPIC' culture and commitment to talent development suggest a stable and growth-oriented environment. Customers benefit from an expanding portfolio of innovative, high-quality scientific tools and diagnostic solutions, enhancing research capabilities and clinical outcomes. The company's global expansion and leadership in protein sciences also contribute to advancements across the broader biotech and pharmaceutical industries.

Risk Assessment

Risk Level: medium — The company's reliance on strategic acquisitions, such as Lunaphore SA in fiscal 2024 and the planned full acquisition of Wilson Wolf by 2027, introduces integration risks and potential dilution. While no single supplier is material, the filing notes that some components require specific qualifications, leading to single or limited suppliers, which could pose supply chain disruption risks. The company operates in highly competitive markets, which could impact future revenue growth and market share.

Analyst Insight

Investors should consider TECH for long-term growth, given its consistent M&A activity and strong position in critical life science and diagnostics markets. Monitor integration progress of recent acquisitions and potential supply chain vulnerabilities, but the company's diversified portfolio and global expansion efforts suggest resilience.

Revenue Breakdown

Key Numbers

• $11.4 billion — Aggregate market value of Common Stock held by non-affiliates (As of December 31, 2024, based on $72.03 per share)
• 155,549,587 — Shares of Common Stock outstanding (As of August 18, 2025)
• 72% — Protein Sciences segment's contribution to net sales (In fiscal 2025, making it the larger segment)
• 28% — Diagnostics and Spatial Biology segment's contribution to net revenues (In fiscal 2025)
• 19.9% — Investment in Wilson Wolf Corporation (Made in fiscal 2023, with full acquisition by 2027)

Key Players & Entities

• BIO-TECHNE Corp (company) — Registrant and parent company
• The NASDAQ Stock Market LLC (regulator) — Exchange where TECH common stock is listed
• Spear Bio (company) — Investment made at the beginning of fiscal 2025
• Lunaphore SA (company) — Acquired at the beginning of fiscal 2024
• Wilson Wolf Corporation (company) — 19.9% investment in fiscal 2023, with full acquisition planned by 2027
• R&D Systems (company) — Key product brand in Protein Sciences segment
• Thermo Fisher Scientific (company) — Distribution partner and licensee of ExoTRU kidney transplant rejection test
• Advanced Cell Diagnostics (company) — Brand for Spatial Biology division products
• Exosome Diagnostics (company) — Brand for Molecular Diagnostics division products
• Asuragen (company) — Brand for genetic and oncology kits

FAQ

Risk Factors

• Intense Competition [high — market]: The company operates in highly competitive markets for life science research, diagnostics, and bioprocessing. Competitors may offer similar or superior products, potentially impacting market share and pricing power.
• Supply Chain Disruptions [medium — operational]: Global supply chain disruptions can affect the availability and cost of raw materials and components, potentially impacting manufacturing operations and the timely delivery of products to customers.
• Intellectual Property Risks [medium — legal]: The company relies on intellectual property for its competitive advantage. Infringement of its patents or proprietary technology, or challenges to its intellectual property rights, could adversely affect its business.
• Regulatory Compliance [medium — regulatory]: The development and sale of diagnostic products are subject to stringent regulatory requirements in various jurisdictions. Failure to comply with these regulations could result in product recalls, fines, or market access restrictions.

Industry Context

Bio-Techne operates within the dynamic and competitive life science research, diagnostics, and bioprocessing markets. The industry is characterized by rapid technological advancements, a strong emphasis on innovation, and increasing demand for tools that enable precision medicine and advanced therapies. Key trends include the growth of spatial biology, cell and gene therapy research, and the need for robust diagnostic solutions.

Regulatory Implications

The company's Diagnostics and Spatial Biology segment is subject to rigorous regulatory oversight from bodies like the FDA and international equivalents. Compliance with quality standards (e.g., GMP) and specific product approval processes is critical for market access and revenue generation. Changes in regulatory landscapes or compliance failures pose significant risks.

What Investors Should Do

1. Monitor segment performance, particularly the growth trajectory of the Diagnostics and Spatial Biology segment relative to the dominant Protein Sciences segment.
2. Evaluate the integration and performance of recent acquisitions (Lunaphore SA, Spear Bio) and the strategic implications of the Wilson Wolf Corporation investment.
3. Assess the company's ability to navigate supply chain risks and competitive pressures through its operational and strategic initiatives.

Key Dates

• 2023-XX-XX: 19.9% investment in Wilson Wolf Corporation — Strategic investment to expand capabilities, with plans for full acquisition by calendar year 2027.
• 2024-XX-XX: Acquisition of Lunaphore SA — Acquisition to bolster the Diagnostics and Spatial Biology segment, aligning with growth strategy.
• 2025-XX-XX: Investment in Spear Bio — Early fiscal year 2025 investment to enhance product offerings and market position.
• 2025-06-30: End of Fiscal Year 2025 — Reporting period for the 10-K, showing strong performance with Protein Sciences as the dominant segment.
• 2027-12-31: Planned full acquisition of Wilson Wolf Corporation — Indicates a long-term commitment to integrating Wilson Wolf's business, subject to potential earlier completion.

Glossary

Protein Sciences segment

One of Bio-Techne's two operating segments, focused on developing and manufacturing high-quality biological reagents, proteomic analytical tools, and services for research, diagnostics, and cell and gene therapy. (This segment is the primary revenue driver, contributing approximately 72% of net sales in fiscal 2025.)

Diagnostics and Spatial Biology segment

The second operating segment of Bio-Techne, which develops and manufactures diagnostic products, including assays, instrumentation for spatial genomic analysis, and genetic/oncology kits. (Represents a significant portion of revenue (28% in fiscal 2025) and is a key area for strategic growth and acquisitions.)

Spatial Biology

A field of biology that studies the spatial distribution and organization of molecules and cells within tissues, enabling a deeper understanding of biological processes and disease. (This is a key focus area for the Diagnostics and Spatial Biology segment, with products like advanced tissue-based in-situ hybridization assays and instrumentation.)

EPIC culture

An internal company culture framework likely emphasizing elements such as Excellence, Passion, Integrity, and Collaboration, aimed at talent development and employee engagement. (Cited as a strategic initiative to foster talent development and enhance the employee experience.)

Year-Over-Year Comparison

While specific comparative numbers are not detailed in this excerpt, the fiscal year 2025 results indicate continued strong performance, with the Protein Sciences segment solidifying its position as the primary revenue contributor (72%). The company's strategy of disciplined acquisitions, including Lunaphore in fiscal 2024 and Spear Bio in fiscal 2025, suggests ongoing investment in growth areas. No new major risks were highlighted beyond existing concerns like supply chain disruptions and competition, implying a stable risk profile compared to the prior year.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value TECH The NASDAQ Stock Mar
• $72.03 — as reported on The Nasdaq Stock Market ($72.03 per share). Shares of Common Stock held

Filing Documents

• tech-20250630x10k.htm (10-K) — 3771KB
• tech-20250630xex4d1.htm (EX-4.1) — 21KB
• tech-20250630xex19.htm (EX-19) — 51KB
• tech-20250630xex21.htm (EX-21) — 8KB
• tech-20250630xex23.htm (EX-23) — 5KB
• tech-20250630xex31d1.htm (EX-31.1) — 14KB
• tech-20250630xex31d2.htm (EX-31.2) — 14KB
• tech-20250630xex32d1.htm (EX-32.1) — 7KB
• tech-20250630xex32d2.htm (EX-32.2) — 7KB
• tech-20250630xex97.htm (EX-97) — 29KB
• tech-20250630x10k005.jpg (GRAPHIC) — 63KB
• 0001558370-25-011716.txt ( ) — 17089KB
• tech-20250630.xsd (EX-101.SCH) — 67KB
• tech-20250630_cal.xml (EX-101.CAL) — 111KB
• tech-20250630_def.xml (EX-101.DEF) — 281KB
• tech-20250630_lab.xml (EX-101.LAB) — 714KB
• tech-20250630_pre.xml (EX-101.PRE) — 570KB
• tech-20250630x10k_htm.xml (XML) — 4122KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 14 Item 1B. Unresolved Staff Comments 28 Item 1C. Cybersecurity 28 Item 2.

Properties

Properties 29 Item 3.

Legal Proceedings

Legal Proceedings 30 Item 4. Mine Safety Disclosures 30 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 30 Item 6.

Selected Financial Data

Selected Financial Data 33 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 46 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 47 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 88 Item 9A.

Controls and Procedures

Controls and Procedures 88 Item 9B. Other Information 89 PART III Item 10. Directors, Executive Officers 89 Item 11.

Executive Compensation

Executive Compensation 89 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 89 Item 13. Certain Relationships and Related Transactions, and Director Independence 89 Item 14. Principal Accounting Fees and Services 89 PART IV Item 15. Exhibits, Financial Statement Schedules 90

SIGNATURES

SIGNATURES 94 2 Table of Contents In this Annual Report, the terms "Bio-Techne" or the "Company" refer to Bio-Techne Corporation, Bio-Techne Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Bio-Techne Corporation, as the context requires. FORWARD-LOOKING INFORMATION AND CAUTIONARY STATEMENTS Certain statements included or incorporated by reference in this Annual Report, in other documents we file with or furnish to the Securities and Exchange Commission ("SEC"), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are "forward-looking statements" within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, pricing, tax rates, tax provisions, cash flows, our liquidity position or other projected financial measures; management's plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, strategic opportunities, dividends and executive compensation; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; future regulatory approvals and the timing and conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Bio-Techne intends or believes will or may occur in the future. Terminology suc

BUSINESS

ITEM 1. BUSINESS OVERVIEW Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. We are a Minnesota corporation with our global headquarters in Minneapolis, Minnesota. We were founded in 1976 as Research and Diagnostic Systems, Inc. We became a publicly traded company in 1985 through a merger with Techne Corporation, now Bio-Techne Corporation. Our common stock is listed on the NASDAQ under the symbol "TECH." We operate globally, with offices in many locatio

View Full Filing

View this 10-K filing on SEC EDGAR